Skip to main content

Month: June 2020

CURE Pharmaceutical [OTCQB:CURR] Expands to Mexico in Collaboration with Factoria Bogar Subsidiary

OXNARD, Calif., June 03, 2020 (GLOBE NEWSWIRE) — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, announced today a collaboration with PMI, a subsidiary of Factoria Bogar in Guadalajara, Mexico. PMI will have access to CURE’s innovative drug delivery platform, CUREform™ for its drug formulation, as well as become its distribution partner in Mexico for CURE’s wellness products, such as its vitamin D supplement, sleep and CBD combination products.“This collaboration enables us to reach new markets with our suite of wellness products as well as prompt innovation with new drug formulations and conduct valuable patient studies on drug efficacy,” said Rob Davidson, CEO of CURE. “This is a valuable partnership from both a revenue perspective as well as an opportunity to expand product offerings and...

Continue reading

BeiGene Announces the Approval of BRUKINSA™ (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma

BEIJING, China and CAMBRIDGE, Mass., June 03, 2020 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its BTK inhibitor BRUKINSA™ (zanubrutinib) has received approval from the China National Medical Products Administration (NMPA) in two indications – the treatment of adult patients with chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL) who have received at least one prior therapy, and the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Both new drug applications (NDAs) were previously granted priority review by the Center for Drug Evaluation (CDE) of the...

Continue reading

Kingsoft Cloud Announces Unaudited First Quarter 2020 Financial Results

BEIJING, June 03, 2020 (GLOBE NEWSWIRE) — Kingsoft Cloud Holdings Limited (“Kingsoft Cloud” or the “Company”) (NASDAQ: KC), a leading independent cloud service provider in China, today announced its unaudited financial results for the first quarter ended March 31, 2020.First Quarter 2020 Financial HighlightsTotal revenues were RMB1,391.0 million (US$1196.4 million) in the first quarter of 2020, representing an increase of 64.5 % year-over-year.Gross profit was RMB70.8 million (US$10.0 million) or 5.1% gross margin in the first quarter of 2020, compared with gross loss of RMB45.1million or -5.3% gross margin in the first quarter of 2019.Non-GAAP gross profit2, was RMB74.2 million (US$10.5 million) or 5.3% Non-GAAP gross margin in the first quarter of 2020, compared with Non-GAAP gross loss of RMB44.6 million...

Continue reading

Hoylu AB: Publishes its Annual Report for 2019 (correction: in the previous PR an incorrect reference was made to MAR, it is now deleted)

Hoylu AB (publ) announced today that the Annual Report for 2019 is available at Hoylu’s web site:https://www.hoylu.com/investor-relations/financial-reports/For more information, please contact:Stein Revelsby, CEO at Hoylu +1 213 440 2499 Email: sr@hoylu.comKarl Wiersholm, CFO at Hoylu +1 425 829 2316 Email: kw@hoylu.comAbout HoyluHoylu’s mission is to make remote work and information sharing easy. Through our customizable Connected Workspaces™ we deliver software solutions for companies, organizations and individuals across virtually all industries that enable all teams, big and small to work efficiently and securely in an intuitive and easy workflow.For more information: www.hoylu.com.

Continue reading

Hoylu AB: Publicerar årsredovisning för 2019 (rättelse: i tidigare PM gjordes en felaktig hänvisning till MAR, den är nu borttagen)

Hoylu AB (publ) meddelar idag att årsredovisningen för räkenskapsåret 2019 finns tillgänglig på bolagets hemsida:https://www.hoylu.com/investor-relations/financial-reports/För ytterligare information, vänligen kontakta:Stein Revelsby, VD på Hoylu + 1 213 440 2499 e-post: sr@hoylu.comKarl Wiersholm, CFO på Hoylu + 1 425 829 2316 e-post: kw@hoylu.comOm HoyluHoylus uppdrag är att göra distansarbete och informationsutbyte enkelt. Genom vår anpassningsbara Connected Workspaces™ levererar vi programvarulösningar till företag, organisationer och individer i praktiskt taget alla branscher som gör det möjligt för alla team, stora som små att arbeta effektivt och säkert i ett intuitivt och enkelt arbetsflöde. För mer information: www.hoylu.comKortnamn: HoyluMarknadsplats: Nasdaq First North Growth MarketCertified Adviser: Mangold Fondkommission...

Continue reading

Resonant Inc. to Participate in the Stifel 2020 Virtual Cross Sector Insight Conference

GOLETA, Calif., June 03, 2020 (GLOBE NEWSWIRE) — Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, is scheduled to participate in a fireside chat at the Stifel 2020 Virtual Cross Sector Insight Conference on Wednesday, June 10, 2020, at 11:20 a.m. ET.Management plans to provide a business update and industry overview focusing on the company’s strategy within its served mobile market and emerging target non-mobile market, in particular giving an update on Resonant’s efforts to bring its industry-leading XBAR® technology to the non-mobile RF filter marketplace. Filters based on XBAR technology address the wide bandwidth, high frequency requirements of new 5G and WiFi devices in both mobile and non-mobile applications.Resonant...

Continue reading

Pain Management Devices Market to Witness 9.1% CAGR; Boston Scientific’s ‘Spectra WaveWriter’ Launch to Enable Growth, says Fortune Business Insights

Pune, June 03, 2020 (GLOBE NEWSWIRE) — The global pain management devices market will benefit from increasing regulatory approvals for neuromodulation devices in recent years. According to a report published by Fortune Business Insights, titled “Pain Management Devices: Global Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 3,922.9 Mn in 2018. Fortune Business Insights states that the market will reach US$ 8,046.3 Mn by 2026, exhibiting a CAGR of 9.4%.Pain management devices aid in reducing chronic pain and other undesirable conditions. Pain management can be used as an alternative to surgery to improve the result of your medication. This allows a non-invasive platform for surgical procedures, which in turn will lead to an increase in the global pain management devices market value. Recent technological...

Continue reading

NaturalShrimp, Inc. CEO Issues JUNE 3, 2020 UPDATE Letter to Shareholders

Dallas, Texas, June 03, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — NaturalShrimp today issued this letter to its shareholders.Dear Fellow Shareholders:As we previously announced in the April 29, 2020 Press Release, the Company and the insurance company have been waiting on the final Fire Marshal’s report that has not been published as of this week. Upon receipt, the Company will post the report on its website: https://naturalshrimp.com. We are excited about all the positive developments for our Company’s strategic direction. This event did not destroy our technology or the tremendous business opportunity it provides. It simply delayed our timeline.The Company’s insurance company, General Star Indemnity Company, has settled and paid in full 100% of our claims which will be more than $917,000. We are happy to announce the Company...

Continue reading

Tonix Pharmaceuticals to Participate in Two June Virtual Investor Conferences

NEW YORK, June 03, 2020 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will participate and host one-on-one meetings at two virtual investor conferences in June.Details are as follows:The Company’s BIO Digital presentation will be made through the BIO Digital website and available on demand to registered participants during the conference at https://www.bio.org/events/bio-digital/sessions/691517.A live webcast and subsequent archived recording of the Company’s presentation at the Virtual Summer Summit will be available under the IR Events tab of the Investor Relations section of the Tonix website at www.tonixpharma.com.About Tonix Pharmaceuticals Holding Corp.Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing,...

Continue reading

AMRYT AND SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA ACROSS 17 JURISDICTIONS IN CENTRAL AND EASTERN EUROPE (“CEE”)

AMRYT PHARMA PLC(“Amryt” or the “Company”)AMRYT AND SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA ACROSS 17 JURISDICTIONS IN CENTRAL AND EASTERN EUROPE (“CEE”)Amryt, a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from serious and life-threatening rare diseases, today announces the signing of a distribution agreement with Swixx BioPharma AG (“Swixx”) of Baar, Switzerland. Under the agreement, Amryt has appointed Swixx as exclusive distributor of  Myalepta® (metreleptin) in the EU territories of Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, Slovakia, Slovenia. In addition, Swixx will distribute Myalepta® for Amryt in the West Balkan countries of Albania, Bosnia and Herzegovina, Kosovo, Montenegro, North...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.